Premium
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Jan. 3, 2025 WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial PR Newswire WALTHAM, Mass...
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting PR Newswire WALTHAM...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Dec. 3, 2024 WALTHAM, Mass., Dec. 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference PR Newswire WALTHAM, Mass., Nov. 27, 2024 WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A...
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib PR Newswire WALTHAM, Mass., Nov. 12, 2024 – Primary endpoint...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.49 | 11.5683229814 | 12.88 | 14.45 | 12.4 | 2450284 | 13.10554127 | CS |
| 4 | -2.6 | -15.3211549794 | 16.97 | 17.155 | 12.4 | 2967508 | 13.60829942 | CS |
| 12 | -3.79 | -20.8700440529 | 18.16 | 22.5 | 12.4 | 2039944 | 15.69409883 | CS |
| 26 | -6.28 | -30.411622276 | 20.65 | 25.07 | 12.4 | 1459122 | 17.44380049 | CS |
| 52 | -7.44 | -34.1127922971 | 21.81 | 25.34 | 12.4 | 1292505 | 19.22480287 | CS |
| 156 | -7.62 | -34.6521145975 | 21.99 | 29.86 | 11.215 | 1046001 | 19.18722548 | CS |
| 260 | 5.8 | 67.6779463244 | 8.57 | 29.86 | 6.32 | 861969 | 18.92550556 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
